Fidaxomicin versus vancomycin for Clostridium difficile infection. - sprookjes - yvandenbroek - TriplyDB

Fidaxomicin versus vancomycin for Clostridium difficile infection.

Fidaxomicin versus vancomycin for Clostridium difficile infection.

http://www.wikidata.org/entity/Q34162172

about

Prospects and challenges for intestinal microbiome therapy in pediatric gastrointestinal disorders Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model.Surgical Management of Clostridium difficile Colitis New target for inhibition of bacterial RNA polymerase: 'switch region'Clostridium difficile infection: a review of current and emerging therapies Microbiome mediation of infections in the cancer setting Fecal microbiota transplantation: in perspective Recent Advances in the Diagnosis and Treatment of Clostridium Difficile Infection Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection Gastrointestinal dysbiosis and the use of fecal microbial transplantation in Clostridium difficile infection Ultrasensitive Detection and Quantification of Toxins for Optimized Diagnosis of Clostridium difficile Infection WSES guidelines for management of Clostridium difficile infection in surgical patients Rational Therapy of Clostridium difficile Infections Clostridium difficile in the ICU: the struggle continues Pseudomembranous colitis Bacteriotherapy for the treatment of intestinal dysbiosis caused by Clostridium difficile infection Clostridium difficile Infection in Children: Current State and Unanswered Questions Clostridial toxins: sensing a target in a hostile gut environment.Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review Recurrent Clostridium difficile infections: the importance of the intestinal microbiota What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?The potential for emerging therapeutic options for Clostridium difficile infection Diversity and Evolution in the Genome of Clostridium difficile Fecal microbiota transplantation and emerging applications Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection Identification of a Novel Lipoprotein Regulator of Clostridium difficile Spore Germination A pilot study of rapid benchtop sequencing of Staphylococcus aureus and Clostridium difficile for outbreak detection and surveillance Prediction tools for unfavourable outcomes in Clostridium difficile infection: a systematic review Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.Antibacterial Resistance in Patients with Hematopoietic Stem Cell Transplantation.Clostridium difficile infection: Updates in management.Clostridium difficile Infection and Fecal Microbiota Transplant.A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection [Clostridium difficile infections in geriatric patients].Clostridium difficile infection: New insights into therapeutic options.Treatment of Clostridium difficile infection using SQ641, a capuramycin analogue, increases post-treatment survival and improves clinical measures of disease in a murine model.Antibiotic Regimen after a Total Abdominal Colectomy with Ileostomy for Fulminant Clostridium difficile Colitis: A Multi-Institutional Study.Clostridium difficile infection: guideline-based diagnosis and treatment Probiotics for Clostridium difficile infection in adults (PICO): Study protocol for a double-blind, randomized controlled trial

P2860

Q24599041-E226E44C-4ECE-4B04-84A5-FE674484F990 Q24616179-9323AC9C-6396-489B-8D69-221180D10642 Q24618413-7D29352A-3729-4A4C-80C8-C3CD070812DE Q24634933-E1A4A312-8CB1-448E-B8CF-E26FC0790973 Q26750157-EEEDC4FD-DF46-4452-81E8-96AB55676440 Q26752672-A21406D8-D5BB-4287-BB37-C7982490443E Q26765214-29D95EA5-5C53-4632-A9ED-5E3D8D9F7DA7 Q26766112-EC9105E1-E460-4DC2-BDA7-CA73404C933E Q26767079-29263A8C-48ED-4DE1-A45B-438CABCF6AD0 Q26770175-58135054-E509-42CE-8CA1-2BE130786013 Q26776155-F1DB9D8D-55E2-43DE-8D74-760CB863E6A1 Q26776411-67F6F15F-B37D-4858-8C8E-6D3CE123B5A1 Q26795429-7DD3278B-A13C-4298-8CD9-54D26A52AFF3 Q26796548-3B27B6B4-778C-467E-B75D-B2BDE86FA0A8 Q26823000-A1153D78-DA60-4F91-9EC3-E3960E336814 Q26865999-BEA1CD07-F436-40D9-B109-2B2914E8DFEB Q27009228-87524A99-1D16-4496-80FD-171CA9AA6EBF Q27016320-C6A187B1-BAAC-43BB-9688-4F9A5E281503 Q27016565-2FB25D6A-7F4A-458D-BF65-F1FF70D8960D Q27021390-0B661CBD-61FB-4287-8483-345EC9F5D8FB Q27023219-EAA620FC-F1EC-4A3F-AA10-A5C4F2D97926 Q27687191-AE759D8F-98F0-4B3A-8C97-E078598E3AFF Q28082059-DD4078C9-FEF2-4C23-AC50-AB0DDF082AF2 Q28084700-8074747D-151F-41DC-A32D-5E9D8F8F5B1E Q28255756-F3FEB774-F69C-4DC9-9081-A6FF206D6CB4 Q28258066-D03A9E41-94AF-468E-969E-161F83D1551A Q28550467-78218B4C-E3FA-4424-AF33-4B40FAC8E0E8 Q28728239-E1A8940A-8595-4AF0-ABD5-1646F4903FD4 Q28732437-9E5BC9C1-C6D9-45D0-9A0D-44A44B97DB6C Q30235446-3872B034-BA6B-4F24-BD5D-6A9EADE35A99 Q30238945-C0748941-FFEA-4562-8939-7F9CBB6C9299 Q30239988-9FC27EA6-A2B3-42EC-BCDD-0DE033F73F70 Q30240065-3AD287C1-51DA-41CD-BFF0-2861A05528AC Q30240264-93B3DC16-214C-4DA7-8847-A66AA71C34F6 Q30244040-AC0C82B2-92F0-41BC-9E42-B2F27EAC85B9 Q30252154-C35D5552-862C-4C07-9544-A7CD3B19591F Q30277636-7C8B5AEF-FD8B-4A85-80C3-74394EAF7316 Q30279196-C8CB2463-90A3-4616-BB87-BF85B10B31AD Q30316981-189DF308-55AD-4C3C-A287-20A562DA5358 Q30354419-0077AA29-F3DA-4745-BFEF-9016EADFE851

P2860

Fidaxomicin versus vancomycin for Clostridium difficile infection.

http://www.wikidata.org/entity/Q34162172

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Fidaxomicin versus vancomycin for Clostridium difficile infection.

@ast

Fidaxomicin versus vancomycin for Clostridium difficile infection.

@en

Fidaxomicin versus vancomycin for Clostridium difficile infection.

@nl

type

label

Fidaxomicin versus vancomycin for Clostridium difficile infection.

@ast

Fidaxomicin versus vancomycin for Clostridium difficile infection.

@en

Fidaxomicin versus vancomycin for Clostridium difficile infection.

@nl

prefLabel

Fidaxomicin versus vancomycin for Clostridium difficile infection.

@ast

Fidaxomicin versus vancomycin for Clostridium difficile infection.

@en

Fidaxomicin versus vancomycin for Clostridium difficile infection.

@nl

P1433

Q34162172-A41D0E0A-78D6-4B70-872F-3E76EFFED9DC

P1476

Q34162172-495BC4EA-8FD6-40E9-A3DF-CFD04A2167DF

P2093

Q34162172-0B670A59-FD5F-4B93-879A-74A18ECE48B2

Q34162172-2554B8E0-95D1-40A9-A92B-68E260851866

Q34162172-523C8392-65FA-4CDF-8CCF-8BCEE1A833F9

Q34162172-6CF2D30C-1350-4F29-B705-9C08C4769222

Q34162172-9EA1B7F3-D410-4285-9CDC-989B20834C1C

Q34162172-A6AFC414-588F-400F-8164-13894519A616

Q34162172-AD5A4BF4-B65D-441A-B4C7-E31CAA95B3DB

Q34162172-BD693BAB-3A3A-4DCE-9533-BB732DB9C17E

Q34162172-DC22E0E2-A021-4B6D-9019-29158713ADAF

Q34162172-EDBFA8C6-59D3-471E-AC41-01330D6CFFDE

P304

Q34162172-977F903D-43C5-4399-9E3E-5C9D698EFA2A

P31

Q34162172-0B9FF473-CBC0-4B7D-A048-E71AA2A99B7E

P356

Q34162172-6A54244F-97A1-442A-8445-13B4BCD3BF48

P407

Q34162172-B3709271-319C-439E-B842-DC456304385B

P433

Q34162172-49C33684-7E99-488D-AA80-7AC0517E6C9D

P478

Q34162172-9E7F60AA-8E1E-43BA-A424-94F608DCE916

P577

Q34162172-3B606CF8-07EE-42FA-AC95-EFA963DD7775

P698

Q34162172-D39D33D8-9E4D-4F62-B153-BE0F33B3B1D4

P921

Q34162172-99A45A67-8D4B-4704-A8F5-0F48F7328AE8

P356

P1433

The New England Journal of Medicine

P1476

Fidaxomicin versus vancomycin for Clostridium difficile infection.

@en

P2093

Arnold Lentnek

http://www.w3.org/2001/XMLSchema#string

Karl Weiss

http://www.w3.org/2001/XMLSchema#string

Kathleen M Mullane

http://www.w3.org/2001/XMLSchema#string

Mark A Miller

http://www.w3.org/2001/XMLSchema#string

OPT-80-003 Clinical Study Group

http://www.w3.org/2001/XMLSchema#string

Pamela Sears

http://www.w3.org/2001/XMLSchema#string

Sherwood Gorbach

http://www.w3.org/2001/XMLSchema#string

Thomas J Louie

http://www.w3.org/2001/XMLSchema#string

Yoav Golan

http://www.w3.org/2001/XMLSchema#string

Youe-Kong Shue

http://www.w3.org/2001/XMLSchema#string

P304

422-431

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA0910812

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

364

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21288078

http://www.w3.org/2001/XMLSchema#string

P921

Clostridium difficile